Abstract
ObjectiveTo study the molecular genetic and clinical features of cerebral cavernous malformations (CCM) in a cohort of Spanish patients.MethodsWe analyzed the CCM1, CCM2, and CCM3 genes by MLPA and direct sequencing of exons and intronic boundaries in 94 familial forms and 41 sporadic cases of CCM patients of Spanish extraction. When available, RNA studies were performed seeking for alternative or cryptic splicing.ResultsA total of 26 pathogenic mutations, 22 of which predict truncated proteins, were identified in 29 familial forms and in three sporadic cases. The repertoire includes six novel non-sense and frameshift mutations in CCM1 and CCM3. We also found four missense mutations, one of them located at the third NPXY motif of CCM1 and another one that leads to cryptic splicing of CCM1 exon 6. We found four genomic deletions with the loss of the whole CCM2 gene in one patient and a partial loss of CCM1and CCM2 genes in three other patients. Four families had mutations in CCM3. The results include a high frequency of intronic variants, although most of them localize out of consensus splicing sequences. The main symptoms associated to clinical debut consisted of cerebral haemorrhage, migraines and epileptic seizures. The rare co-occurrence of CCM with Noonan and Chiari syndromes and delayed menarche is reported.ConclusionsAnalysis of CCM genes by sequencing and MLPA has detected mutations in almost 35% of a Spanish cohort (36% of familial cases and 10% of sporadic patients). The results include 13 new mutations of CCM genes and the main clinical symptoms that deserves consideration in molecular diagnosis and genetic counselling of cerebral cavernous malformations.
Highlights
Cerebral Cavernous Malformations (CCMs; OMIM 116860) are enlarged vascular cavities without intervening brain parenchyma with an estimated prevalence in the general population close to 0.1–0.5 percent
We report the identification of 13 novel mutations in the CCM genes, including the activation of a cryptic splicing signal
CCM3 We studied CCM3 by MLPA and sequencing in CCM1- and
Summary
Cerebral Cavernous Malformations (CCMs; OMIM 116860) are enlarged vascular cavities without intervening brain parenchyma with an estimated prevalence in the general population close to 0.1–0.5 percent. Single or multiple malformations may develop, which can lead to cerebral haemorrhage (30–40%), seizures (40–70%), headache (10–30%) and focal neurological symptoms (35–50%). The onset age is variable with higher incidence between 10 and 40 years. CCM may occur sporadically or with an autosomal dominant inheritance pattern with variable expression and incomplete penetrance. Almost 25% of CCM carriers remain symptom-free throughout their lives. Genes responsible for CCM were mapped [1] and located on 7q21.2 (CCM1, KRIT1) [2,3], 7p13 (CCM2, MGC4607) [4] and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.